In some cancers including colorectal cancer, the blockade of CTLA-4 or PD-1 does not achieve an ideal therapeutic effect and incentivizes the efforts to locate other immune checkpoint inhibitors, such as TIM3. Here, PDCD1 is linked to cancer.